Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 3/20 | 0.73 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25325869 | 0.88 | F11 (0.56) | F11XDHKDM4EHSD17B10MAPT | |
| SCHEMBL26107615 | 0.84 | F11 (1.00) | F11XDH | |
| SCHEMBL25327616 | 0.82 | XDH (0.60) | F11XDH | |
| SCHEMBL30771634 | 0.82 | XDH (0.60) | F11XDH | |
| SCHEMBL25328209 | 0.82 | KDM4E (0.56) | F11XDHKDM4EMAPTALDH1A1 | |
| SCHEMBL25915074 | 0.81 | XDH (0.60) | F11XDH | |
| SCHEMBL25325875 | 0.81 | F11 (0.72) | F11XDHKDM4EMAPTALDH1A1 | |
| SCHEMBL25326523 | 0.78 | KDM4E (0.47) | F11KDM4EHSD17B10MAPTALDH1A1 | |
| SCHEMBL28746434 | 0.75 | MAPT (0.56) | KDM4EHSD17B10MAPTALDH1A1RAB9A | |
| SCHEMBL469731 | 0.75 | CDC7 (0.58) | XDHKDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105881-B | Platelet aggregation inhibitor, and preparation method and application thereof | 沈阳海诺威医药科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| EP-3960734-B1 | PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF | SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) | 2023-10-11 | — | — | EP | claimed |
| US-11713300-B2 | Platelet aggregation inhibitor, preparation and uses thereof | SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-08-01 | — | — | US | claimed |
| CN-114105881-A | Platelet aggregation inhibitor and preparation method and application thereof | 沈阳海诺威医药科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-114105881-B | Platelet aggregation inhibitor, and preparation method and application thereof | 沈阳海诺威医药科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3960734-B1 | PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF | SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-3960734-B1 | PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF | SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11713300-B2 | Platelet aggregation inhibitor, preparation and uses thereof | SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-08-01 | — | — | US | disclosed |
| US-11713300-B2 | Platelet aggregation inhibitor, preparation and uses thereof | SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-08-01 | — | — | US | disclosed |
| US-11713300-B2 | Platelet aggregation inhibitor, preparation and uses thereof | SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-08-01 | — | — | US | disclosed |
| CN-114105881-A | Platelet aggregation inhibitor and preparation method and application thereof | 沈阳海诺威医药科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713300-B2 | Platelet aggregation inhibitor, preparation and uses thereof | TFPI, F12, TFPI2 | F11 7/4885XDH 413/4885KDM4E 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.